Medicines Co. Stock
-
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
Cons
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -1.530% | 2.541% | 0.106% | 0.929% | 0.929% | -10.397% | -12.485% |
| Opko Health Inc. | -1.850% | 2.406% | -0.638% | -21.687% | -21.541% | 4.327% | -70.394% |
| Amicus Therapeutics Inc. | 30.430% | 1.099% | 13.580% | -1.075% | 0.546% | -17.087% | -54.000% |
Comments
News
Meet the Biotech Stock That Just Jumped 251% Higher
Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue


